Aytu Bioscience Inc., of Englewood, Colo., and Innovus Pharmaceuticals Inc., of San Diego, filed a joint preliminary proxy statement/prospectus with the SEC regarding Aytu's proposed acquisition of Innovus. Aytu plans to retire all Innovus outstanding common stock for up to $8 million shares of Aytu common stock. When the deal is complete, Aytu will have more than 35 consumer products for treating diabetes, men's health, sexual wellness and respiratory health.

Emmaus Life Sciences Inc., of Torrance, Calif., said it is expanding into the Middle East and North Africa with the Sultanate of Oman’s Taiba Healthcare and its early access program for Endari (L-glutamine oral powder) to reduce acute complications of sickle cell disease in adult and pediatric patients 5 and older. Emmaus expects to receive requests for entry to the early access program in the first quarter of 2020.

Genix Pharmaceuticals Corp., of Vancouver, British Columbia, will buy 30 World Health Organization-approved generic prescription ophthalmic drugs and their CTD dossiers from Canagen Pharmaceuticals Inc., of Richmond, British Columbia, with global sales and marketing rights (excluding India), for $750,000 in common shares. Among the products Genix is buying are Sucanon, a nutraceutical for managing and treating diabetes, and Renochlor, a nutraceutical to prevent and treat chronic kidney and end-stage renal disease.

Gilead Sciences Inc., of Foster City, Calif., and Tokyo’s Eisai Co. Ltd. will distribute and co-promote filgotinib, an oral, selective JAK1 inhibitor, in Japan, to treat rheumatoid arthritis. Gilead Japan retains manufacturing and marketing duties while Eisai will handle distribution. The companies will jointly commercialize the medicine if it is approved.

Lineage Cell Therapeutics Inc., of Carlsbad., Calif., entered license agreements with three unnamed cell therapy companies, each relating to different parts of Lineage’s intellectual property portfolio. All three companies have ongoing commercial operations, including their cell therapy-related assets. The aggregate up-front cash payment from the transactions was greater than $1 million, with additional cash and royalties due upon reaching certain development milestones or product sales.

Newlink Genetics Corp., of Ames, Iowa, said it entered an exclusive worldwide license agreement with London-based Ellipses Pharma Ltd. for the development of, and rights to commercialize, NLG-207 (formerly CRLX-101), a nanoparticle formulation of the topoisomerase 1 inhibitor camptothecin. Ellipses has purchased Newlink’s inventory of NLG-207-related materials, and Newlink will have the potential to receive future royalty payments or a share of any future economics related to the product. As part of the license agreement, Ellipses also gained the rights to develop and commercialize CRLX-301, a nanoparticle formulation of docetaxel that has completed a phase Ia study.

Sosei Group Corp., of Tokyo, said its strategic alliance partner, Pfizer Inc., of New York, has nominated a third clinical candidate, an oral small molecule targeting a G protein-coupled receptor (GPCR) implicated in metabolic and other diseases, from their multitarget drug discovery collaboration. This event triggered a $3 million payment to Sosei Heptares. The collaboration was signed in 2015 to research and develop potential new medicines directed at up to 10 GPCR targets across multiple therapeutic areas. Many of those targets have clinical or biological validation as key points for therapeutic intervention potentially targeting a range of diseases but have proved difficult to address with conventional discovery approaches because of inherent technical challenges.

No Comments